We assessed long-term outcome in 155 patients who had undergone an allogeneic/syngeneic stem cell transplant (SCT) and were in complete remission for more than 2 years after transplant. Probability of late transplantrelated mortality was 6%, and affected only patients with chronic graft-versus-host disease (cGVHD). Thirteen percent of patients experienced relapse. Overall survival projected at 10 and 15 years was 83% and 76%, respectively. Secondary malignancies occurred in two patients, 7.5 and 11 years after SCT. Three female and four male patients parented children 19 to 84 months after SCT. Quality of life (QoL) was assessed in a cross-sectional study by the means of a 30-item questionnaire (QLQ-C30) of the EORTC. The questionnaire was sent to 127 patients remaining alive and answered by 106 patients. Seventy-three percent reported a good to very good QoL within 5 years after SCT and 78% after this time point. However, patients with cGVHD had significant impairment of physical, role and social functioning and only 60% of them were fit for work. These results from long-term survivors show that high cure rates with good to very good QoL can be achieved by allogeneic or syngeneic SCT.
dose therapy prior to SCT, stem cell graft manipulation and occurrence of graft-versus-host disease (GVHD). 7 Despite improvements in myeloablative conditioning regimens 8, 9 and supportive care including use of new generation broadspectrum antibiotics, antiviral and antifungal drugs, [10] [11] [12] human leukocyte antigen (HLA)-typing and donor selection, 13 and prevention and treatment of GVHD, 14, 15 transplant-related complications have remained a major problem of SCT. In contrast to autograft patients, treatment-related deaths after allogeneic SCT are observed not only in the early phase after SCT but also in later years, especially in patients with chronic GVHD not responding to immunosuppression. 16, 17 Recently, an increased rate of secondary malignancies has been reported 1.4 to 221 months after allogeneic or syngeneic SCT. 18, 19 Thus, lifelong monitoring of patients after SCT seems advisable. To date a few assessments on quality of life (QoL) in long-term SCT survivors have been reported. [20] [21] [22] Issues of the long-term side-effects of intensive therapies, return to prior activities and reconstitution of normal levels of functioning are of tremendous importance for patients and their relatives in the decision-making process leading to admittance for or refusal of SCT. We therefore retrospectively analyzed the long-term outcome of 155 adult patients who were alive and in continuous complete remission (CCR) more than 2 years after allogeneic stem cell transplantation for various hematological and oncological diseases. Patients were assessed for late toxicity and risk of relapse. Furthermore, we sent a QoL questionnaire to 127 patients still alive at the time of our survey. One hundred and six patients answered and a cross-sectional assessment of their QoL was performed.
Patients and methods

Patients
Between November 1978 and May 1998, 307 patients with acute leukemia (AL, n = 131), chronic myeloid leukemia (CML, n = 96), multiple myeloma (MM, n = 9), myelodysplastic syndrome (MDS, n = 12), non-Hodgkin's lym-phoma (NHL, n = 29), severe aplastic anemia (SAA, n = 24), paroxysmal nocturnal hemoglobinuria (PNH, n = 2), osteomyelofibrosis (OMF, n = 2), Hodgkin's disease (n = 1) and testicular cancer (n = 1) underwent SCT at our institution. Stem cell donors were identical twins (n = 8), HLAidentical siblings (n = 239), one-antigen (n = 1) or twoantigen (n = 1) mismatched family members, HLAidentical unrelated donors (n = 45), one-antigen (n = 10) or two-antigen (n = 3) mismatched unrelated donors. Patients were categorized as standard risk if they had acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) in first complete remission (CR1), CML in first chronic phase (CP1), NHL in first partial remission (PR1) or testicular cancer. All others were categorized as high risk. One hundred and seventy-eight patients were assigned to the high risk and 129 to the low risk group. During the first 2 years after SCT, 152 patients died, either due to relapse (n = 65 including 51 patients categorized as high risk) or transplant-related complications (n = 87 including 54 patients in the high risk group).
One hundred and fifty-five patients remained disease-free for 2 or more years after SCT and are subjects of the present analysis. Their pre-transplant characteristics are shown in Table 1 . Written informed consent was obtained from all patients. Data were analyzed as of 15 March 2001. The conditioning regimens used for transplantation were those given at our institution during the time period patients were transplanted. The majority of patients received total body irradiation (TBI, 12-13.2 Gy) and cyclophosphamide n = number; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; MM = multiple myeloma; MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma; SAA = severe aplastic anemia; TBI = total body irradiation; GVHD = graft-versus-host disease; MTX = methotrexate; CsA = cyclosporine A; MP = methylprednisone; BM = bone marrow; PBSC = peripheral blood stem cells; HLA = human leukocyte antigen.
(CY, total dose 120 mg/kg b.w. 
Supportive care
Patients were hospitalized in isolation rooms with laminar air-flow or reverse isolation. They received antimicrobial prophylaxis with nonabsorbable antibiotics and Pneumocystis carinii prophylaxis with cotrimoxazole. For cytomegalovirus (CMV) prophylaxis patients received CMVhyperimmunoglobulin until 1993 and thereafter acyclovir as described. 12 Pre-emptive gancyclovir was given in cases of CMV reactivation as tested by pp65 antigenemia assay or polymerase chain reaction, in recent years. Packed red blood cells (RBC) were given to maintain hemoglobin concentrations above 8.0 g/dl and single donor platelet transfusions from CMV-negative donors to keep platelet counts above 20 ϫ 10 9 /l. All blood products were leukocyte depleted and irradiated with 30 Gy.
GVHD prophylaxis, diagnosis and therapy
For GVHD prophylaxis, methotrexate (MTX) alone was given to 21 patients, cyclosporine A (CsA) and methylprednisone to five and CsA alone to eight patients. Since 1987 the majority of patients (n = 115) have received CsA and MTX according to the Seattle protocol. 15 CsA levels were monitored by a monoclonal radioimmunoassay and a level of 200 to 250 ng/ml was considered optimal. Tapering of CsA started after day 100 if no signs of GVHD were present and CsA was discontinued around day 180. The clinical diagnosis of GVHD was confirmed by appropriate biopsies and clinically graded as 0 to IV by the criteria for acute GVHD, and as none, limited or extensive for chronic GVHD. 23, 24 Treatment of acute GVHD was started in patients presenting with grades II or more and consisted of corticosteroids (2 mg/kg b.w. per day). In patients resistant to steroid treatment antithymocyte globulin or extracorporeal photochemotherapy (ECP) was administered. 14 Patients with chronic GVHD were mostly treated with CsA and corticosteroids (1 mg/kg b.w.) as described. 25 
Assessment of long-term sequelae
Patients 2 years beyond SCT were seen in the outpatient clinic every 6 months for the first 3 years and yearly thereafter, had a physical examination and blood drawn to check peripheral blood cell counts, their immunologic status, liver, kidney, thyroid and gonadal function. In females, gynecologic examinations were performed every 6 months. If appropriate, radiologic and histologic evaluations were then undertaken. Patients were asked to come lifelong once a year to our outpatient clinic.
Evaluation of quality of life
For evaluation of QoL, patients received a questionnaire (QLQ-C30) created by the European organization for research and treatment of cancer (EORTC) quality of life study group, which is a multidimensional, cancer-specific and cross-culturally tested 30-item questionnaire to assess self-reported QoL. 26 This questionnaire was chosen to make our data comparable to other European studies published on SCT patients. 27 The 30-item questionnaire is composed of scales evaluating global quality of life, physical, role, emotional, cognitive and social function. Three symptom scales evaluate nausea/vomiting, pain and fatigue, while five single items assess dyspnea, diarrhea, appetite loss, sleep disturbances and constipation. The response categories are either dichotomous as yes or no, with four categories: 'not at all', 'a little', 'quite a bit' or 'very much', or as a modified visual analogue scale going from 1 to 7. All scores were linearly transformed to a 0 to 100 scale. Higher scores on the functioning scales and the global quality of life scale indicate better functioning, while higher scores on the symptom scales reflect more problems. For the analysis, results on the global quality of life were summarized in very poor (0-20), poor (21-40), intermediate (41-60), good (61-80) and very good (81-100). Symptom scales were summarized as none to slight (0-29), moderate (30-69) and severe (70-100). Additionally, patients were asked if they were fit for work, irrespective of their having a job or not. In October 2000, questionnaires on QoL after SCT were sent to those 127 patients alive at the time of our survey. One hundred and six of 127 patients (83%) responded and were included in our analysis of QoL. Forty-five percent of these are women and 55% men. Eighty-one percent had a related and 19% an unrelated stem cell donor. In 37 patients (35%) SCT was 2-5 years ago whereas 69 (65%) were more than 5 years after SCT.
Statistical methods
Overall survival, transplant-related mortality and relapse rates were estimated using the method of Kaplan and Meier. Comparisons were based on the generalized Wilcoxon and the log-rank test. Comparisons of global quality of life, physical, role and social functioning between patients with or without chronic GVHD were based on the Mann-Whitney U test. A P value Ͻ0.05 was considered to indicate statistical significance.
Results
Chronic GVHD and late transplant-related mortality
Six patients received syngeneic stem cell grafts. Of 149 patients transplanted with stem cells from sibling or unrelated donors 35 patients (23%) experienced limited and 46 (31%) extensive chronic GVHD at some time after SCT. One of these patients developed severe bronchiolitis obliterans and is in very good condition 2 years after doublelung transplantation. 28 Eight patients with extensive chronic GVHD were receiving immunosuppressive treatment with
Bone Marrow Transplantation
CsA (n = 3), CsA and steroids (n = 1), FK506 (n = 1), FK506 and steroids (n = 1), mycophenolate mophetil (n = 1) and azathioprine (n = 1) at the last contact, whereas in 31 patients chronic GVHD has resolved. Two patients with extensive chronic GVHD died of bronchiolitis obliterans and another three (one with limited chronic GVHD), of multi-organ failure due to severe infection 36, 41 and 55 months after SCT. One patient with SAA who had experienced extensive chronic GVHD with ulcerating lesions of the skin and who had received long-lasting immunosuppressive treatment developed an anaplastic squamous cell carcinoma of the skin 11 years after SCT and died 6 months later despite surgical intervention. 29 One patient developed hepatitis B and C about 6 months after SCT and died of hepatic failure 16 years after SCT. Probability of late TRM for all patients projected at 10 and 15 years is 4% and 6%, as shown in Figure 1 . Late TRM at 10 and 15 years is significantly different in patients with or without chronic GVHD (5% and 12% vs 0%, P = 0.013). Probability of secondary malignancies projected at 10 and 15 years is 1% and 4%, respectively.
Relapse
Nineteen (13%) patients (ALL n = 1, AML n = 6, CML n = 8, NHL n = 2, MM n = 2) experienced relapse 24 to 142 months after SCT. Probability of relapse beyond 2 years after allogeneic stem cell grafting projected at 10 and 15 years is 13% and 16% for the whole cohort, 16% and 16% for patients with AML and 16% and 23% for patients with CML, respectively. In AML patients the latest relapse occurred 6.6 and in CML patients 12 years after SCT, respectively, as shown in Figure 2 .
After recurrence of disease, patients were given conventional chemotherapy (ALL n = 1, AML n = 2, CML n = 3, MM n = 1, NHL n = 2), second allogeneic stem cell transplantation (AML n = 2, CML n = 1), second syngenic transplantation followed by third SCT from an unrelated donor (CML n = 1) or donor leukocyte infusions (DLI) (AML n = 2, CML n = 3, MM n = 1). Eight of nine patients receiving conventional chemotherapy for treatment of relapse died due to disease whereas one patient with MM is still alive with disease 5 years after relapse. Three of four patients given another SCT died between 25 and 31 days later of transplant-associated complications and one patient with CML is currently in molecular remission 41 months after 2nd SCT. 30 Following treatment with DLI, three patients (AML n = 2, CML n = 1) responded transiently. Currently, three (CML n = 2, MM n = 1) are alive with disease 7, 35 and 48 months after DLI infusion, respectively.
Overall survival and long-term sequelae
After a median observation time of 6 years (range, 2-18.5 years), 127 of 155 patients (82%) are currently alive. Six patients were lost to follow-up 6 to 14 years after SCT, 14 died of relapse, seven of transplant-related causes and one patient died of myocardial infarction 15 years after SCT. Overall survival projected at 10 and 15 years is 83% and 76% for the whole cohort, 77% and 58% for patients with AML and 80% and 80% for patients with CML ( Figure  2 ). Two patients (1.3%) developed secondary malignancies. One patient with AML in CR1 had received TBI at a dose of 12 Gy and CY (120 mg/kg b.w.) as conditioning therapy and developed an anaplastic squamous cell cancer of the lip 7.5 years after SCT. After surgical resection and local irradiation he has been disease-free for 26 months. Another patient died from anaplastic squamous cell cancer 12 years after SCT, as described above.
Pregnancies
Three female and four male patients parented children 19 to 84 months after SCT as shown in Table 2 . Delivery by caesarean section was necessary in one patient with vaginal sclerosis caused by chronic GVHD whereas six deliveries were uneventful. Three newborns showed peri-and postpartal problems: one required blood exchange because of maternal-fetal rhesus incompatibility, one had persistence of the fetal circulation which was surgically corrected and one suffered from prolonged newborn jaundice which resolved without treatment. 31 The neonatal course of the other four children was uneventful and the offspring are alive and well.
Quality of life
The mean global QoL was good (mean group score 73.2; s.d. 23.5). Fifty percent of all patients enjoyed a very good global QoL (score 81-100), 26% had a good (score 61-80), 14% an intermediate (score 41-60), 6% a poor (score 21-40) and 4% a very poor (score Ͻ21) global QoL as shown in Figure 3a . More detailed analyses revealed distinct differences in global QoL dependent on the time elapsed since SCT. Whereas 2 to 5 years after SCT 73% of patients had a good to very good global QoL, this was reported from 79% of patients more than 5 years after SCT as shown in Figure 3b and c. Within the functioning subscales, role, emotional and social functioning were the most obviously impaired as shown in Figure 4 . Patients more than 5 years after SCT reported better role, cognitive and social functioning compared to patients 2 to 5 years after SCT.
Eighteen percent of all patients reported no or minimal physical complaints, whereas 25% suffered severely from at least one symptom and another 7.5% from three or more symptoms. Fatigue, dyspnoea and sleep disturbances were the most frequently reported symptoms as shown in Figure  5 . At the time of our survey 74% of all participants were fit for professional work.
Fifty-three of 106 (50%) had developed chronic GVHD at some time after SCT. There was no statistical difference in global QoL between patients with and without chronic GVHD (mean score 71 Ϯ 22 s.d. vs 76Ϯ 25 s.d.). Compared to patients never experiencing chronic GVHD means of physical, role and social functioning were significantly lower (P Ͻ 0.05) whereas no difference in emotional and cognitive functioning between those two groups was observed (Table 3) . Patients in the chronic GVHD group reported significantly more fatigue, pain and constipation (P Ͻ 0.05). Only 60% of patients who had developed chronic GVHD were fit for professional work.
Discussion
The purpose of this study was to evaluate the long-term outcome of patients given allogeneic or syngeneic SCT for various hematological and oncological diseases at a single transplant center. We observed that in patients who are in CR for more than 2 years after SCT the probability of overall survival is 83% at 10 and 76% at 15 years after SCT which is comparable with other reports. 16, 17 In a European Group for Blood and Marrow Transplantation (EBMT) study on long-term outcome of patients with acute leukemia -alive and disease-free 2 years after bone marrow transplantation -an event-free survival of 82% after 9
Bone Marrow Transplantation Bone Marrow Transplantation years, regardless of the subtype of leukemia, stage of disease at transplant and stem cell source, was reported. 16 Whereas in our study overall survival of CML patients was 80% both after 10 and 15 years, a further decline in overall survival was observed in patients with acute leukemia over time. This finding is most likely due to small patient numbers. The major cause of death in our study was late recurrence of malignant disease which was observed in 13% of our patients, with the latest occurring 12 years after SCT for CML. In patients with acute leukemia, the latest relapse was seen 6.6 years after SCT, which is similar to previous reports. 16, 17, 32 Thus, disease-free survival does not reach a stable plateau and long-term monitoring especially in patients with molecular disease markers, eg CML is warranted. This would allow early administration of salvage therapy including DLI, where in CML patients complete remissions were achieved in 82% of patients in cytogenetic relapse and in 78% of those in hematologic relapse. 33 In our study population investigated 2 years after SCT and in CR, occurrence of acute or chronic GVHD had no influence on risk for relapse which confirms results previously reported. 16 The probability of late TRM in our study of 6% at 15 years compares favorably with previous reports. 17 Only chronic GVHD had a statistically significant impact (P = 0.013) on transplant-related mortality in our patients, leading to late deaths due to obstructive and restrictive lung disease or severe opportunistic infection. Recently, it was demonstrated that the presence of chronic GVHD requiring immunosuppressive therapy 2 years after SCT identifies a group of patients at high risk for non-relapse death. 17 The incidence of secondary cancers in our study was low at 1.3% after a median follow-up of 73 months (range, 27.6-222 months), which compares favorably with other reports. 18, 19 Curtis et al 19 reported a significantly higher risk of new solid tumors with 2.2% at 10 and 6.7% at 15 years after SCT. There, chronic GVHD and male sex were strongly linked with an excess risk of squamous cell cancer of the buccal cavity and skin. In our study, the only secondary cancers observed were affecting skin and oral mucosa of patients with extensive chronic GVHD. All these findings thus strongly support the need for lifelong surveillance of patients after SCT.
In our survey, pregnancies occurred in three patients and four partners of patients who had undergone SCT. So far, only a minority of patients given TBI containing condition- Table 3 Mean scores of functioning scales in patients with and without chronic GVHD ing experiences recovery of gonadal function. 34 Furthermore, an increased rate of spontaneous abortion in patients receiving TBI-containing conditioning regimens and a higher risk for pre-term labor and delivery of low birth weight (1.36 to 2.24 kg) infants has been reported. 34 In view of the excellent long-term results of SCT including high overall survival rates, cryopreservation of gonadal cells prior to SCT should be offered to younger patients to allow parenthood after SCT.
The mean global quality of life of our patients is good and comparable with results observed in a Norwegian study in patients 1 year after SCT. 21 As in other reports we found a better QoL beyond 5 years after SCT with 79% of patients having a good to very good global QoL compared to 73%, 2 to 5 years after SCT. 22 Whether this is an actual improvement over time or results from drop out of patients with more serious health impairment cannot be answered due to the cross-sectional design of our study, but does need to be evaluated by a long-term prospective study. Physical, role and social functioning scores in our long-term survivors were lower when compaired to a normal population analyzed by Hjermstad et al 21 Our results are in agreement with findings reported by Hjermstad et al. 21 and Sutherland et al 20 who used a different questionnaire in comparing SCT patients with a normal population. In our study physical, role and social functioning scores were significantly lower in patients experiencing chronic GVHD compared to patients without chronic GVHD. This observation has also been reported in a prospective longitudinal study by Syrjala et al 35 where patients with more severe chronic GVHD had an impaired physical and psychosocial recovery at 1 year after SCT. Knowing about the deficits in these functional scales after SCT should have direct clinical implications for counseling of patients and their relatives. Realistic information from the staff about the often lengthy rehabilitation periods before resumption of prior activities is important. Knowing what to expect might help patients to reduce their frustration about shortcomings in the fulfilment of working and social roles. 36 Fatigue, dyspnea and sleep disturbances were the most frequently reported symptoms in our study. This is in agreement with other reports in long-term transplant survivors and prohibitive for normal functioning. 20, 21, 27, 35 Fatigue and dyspnea decreased in patients more than 5 years after SCT. In patients with chronic GVHD significantly more fatigue, pain and constipation were observed. Seventy-four percent of patients are fit for work which is encouraging and comparable with recently reported findings. 37 In conclusion, in patients who are disease-free 2 years after SCT, the probability of cure is high and the prospects of long-term survival with good quality of life are excellent. There is still a substantial percentage of patients whose QoL is lower than would be desirable and symptoms like fatigue and sleep disturbances are, at least in moderate form, frequent among long-term survivors. Larger prospective studies with longer follow-ups are warranted to address the various aspects of QoL after SCT and appropriate psychological support should be available for these patients. Since deaths can occur years later after allogeneic SCT due to relapse, chronic GVHD, or secondary malig-nancies lifelong monitoring of these patients in the outpatient clinic is warranted.
